Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
OPTIMA MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln | |||||
16.01. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.01.2024 | 668 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 16.01.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.01.2024ISIN NameAU0000050981 SEZZLE... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 4,098 | +1,74 % | Aurora Cannabis Inc (3): Aurora Cannabis releases new recreational products | ||
CANOPY GROWTH | 3,750 | +5,19 % | Jetzt wird es brenzlig: Kurse von Tilray, Canopy & Co. brechen massiv ein. So heftig könnte es werden | © Foto: Piyapong Thongdumhyu - 123rf StockfotoRund um die US-Wahl fielen weitere Entscheidungen. Während der Cannabis-Sektor die Wahl Trumps zum nächsten US-Präsidenten noch nicht so ganz einordnen... ► Artikel lesen | |
TILRAY BRANDS | 1,264 | +2,85 % | Tilray Brands, Inc.: Redhook Brewery and Montlake Futures Team Up to Launch Montlake Gameday Gold Lager, a New Craft Beer in Support of University of Washington Athletes | ||
ABBOTT LABORATORIES | 109,92 | -0,07 % | Insulet Says Omnipod 5 AID System Now Compatible With Abbott's FreeStyle Libre 2 Plus CGM Sensor | NORTH CHICAGO (dpa-AFX) - Insulet Corp. (PODD), a provider of tubeless insulin pump technology, announced Wednesday that the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible... ► Artikel lesen | |
SINOPHARM | 2,494 | -3,37 % | Sinopharm Group-Aktie mit Kursverlusten (2,475 €) | Im Wertpapierhandel notiert das Wertpapier der Sinopharm Group zur Stunde leichter. Der jüngste Kurs betrug 2,48 Euro. Für Inhaber der Sinopharm Group ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
AMARIN | 0,478 | +2,58 % | Amarin Corporation plc: Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update | -- Cash Position of $307 Million Provides Stable and Strong Capital Foundation --- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 14,845 | -3,88 % | Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan | ||
CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
AURINIA PHARMACEUTICALS | 7,558 | -3,40 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
BRIDGEBIO PHARMA | 22,180 | +1,42 % | BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market | ||
ARGENT BIOPHARMA | 0,104 | -15,45 % | Argent Biopharma - Valuation report | We value Argent at an un-risked net present value (NPV) of US$1.1bn. Adjusting for the company's specified probabilities of success (PoS) for its three clinical programmes gives a risk-adjusted NPV... ► Artikel lesen | |
CENTR BRANDS | 0,011 | -78,29 % | XFRA 303: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCENTR BRANDS CORP.... ► Artikel lesen | |
LABORATORIOS FARMACEUTICOS ROVI | 61,50 | -0,97 % | Dividendenbekanntmachungen (08.07.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACINQUE SPA IT0001382024 - 0,085 EUR AFC GAMMA INC US00109K1051 0,15 USD 0,1383 EUR BANK OF CHINA LTD CNE1000001Z5 0,259 HKD 0... ► Artikel lesen | |
HERON THERAPEUTICS | 0,991 | -7,21 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance | Reported positive YTD 2024 Adjusted EBITDA of $1.4 million
Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million
ZYNRELEF® (bupivacaine... ► Artikel lesen | |
AVECHO BIOTECHNOLOGY | 0,001 | -85,71 % | AVECHO BIOTECHNOLOGY LIMITED: September 2024 Quarterly Activities Report & Appendix 4C |